More accurate, predictive biomarker analysis may assist in the selection of effective combinatorial immunotherapy treatments for patients. Additionally, the complexity of both the tumor and tumor microenvironment suggests a comprehensive approach is needed for robust characterization of the cancer ecosystem. The search continues to ascertain biomarkers that will improve the selection of patients who will best respond to immunotherapies and help tailor these promising treatments. By combining highly sensitive, exome-scale DNA and RNA sequencing with advanced analytics, ImmunoID NeXT provides a multidimensional view of the tumor and the tumor microenvironment (TME) from a single sample preparation. The platform investigates key aspects of immuno-oncology; from elucidating mechanisms of tumor escape and detecting neoantigens, to identifying novel biomarker signatures and characterizing the immune repertoire.
This presentation will focus on the current challenges facing investigators in immuno-oncological translational research including maximizing data generation from a single sample and the analysis of complex data. We will feature a case study demonstrating the ability of this immunogenomics profiling platform to uncover tumor escape mechanisms and to identify composite biomarkers of potentially greater predictive capacity from patients treated with immune checkpoint blockade. Additionally, we’ll highlight our NeXT Liquid Biopsy, an exome-wide liquid biopsy approach combined with ImmunoID NeXT™, to further explore critical areas of tumor biology.
Dr. Newburn joined Personalis as a Field Applications Scientist in 2013 with over 12 years of research experience in the areas of molecular biology, genetics, and biotechnology. As the Director, Field Applications Scientist, Erin’s team has the responsibility of providing both pre- and post-sale technical support for the Personalis ImmunoID NeXT Cancer Portfolio.
Erin completed her postdoctoral training at the National Institute of Mental Health (NIMH) investigating candidate susceptibility genes for major psychiatric illnesses. Erin received her Ph.D. from the Ohio State University in Integrated Biomedical Science as a Presidential Fellow.
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.